Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Link to relevant study record(s)

Description of key information

A TK assessment of all available data concluded that from the data available so far there is no evidence that the test substance is absorbed via the gastrointestinal tract following oral administration or via the skin following dermal administration.

Key value for chemical safety assessment

Bioaccumulation potential:
no bioaccumulation potential

Additional information

Toxicokinetic Assessment

No specific study has been performed on the absorption/distribution/metabolism/excretion (ADME) of Sakuralube S-900.However, data are currently available fromin vivotoxicology studies performed with this substance.

Sakuralube S-900 is an additive for lubricant, it is a dark brown paste/viscous liquid,with a high molecular weight 920 -1200 and a Log P value of >4.64. It has a low water soluble (<1.09x10-4g/L).These physicochemical properties suggest that Sakuralube S-900 will not be readily absorbed across biological membranes. It is expected to have a low bioavailability but have the potential to bioaccumulate.Sakuralube S-900 is not volatile (2.0x10-20Pa at 25°C) and has a high boiling point (the test material decomposes at 515 ±0.5K without boiling but the estimated boiling point =633K (360°C), based on vapour pressure data and chemical structure) therefore the inhalation route will not be a route of exposure. 

 

Absorption

 

Oral route

During acute oral studies in rats all behavioural, clinical and physiological responses after administration were considered normal. The oral LD50 for Sakuralube S-900 was >2000 mg/kg body weight in rats. Without pharmacokinetic data it is difficult to say if absorption occurred in these studies.

Dermal route

It is generally accepted that compounds with a partition coefficient in the range of 1 to 4 (optimally between 1 and 2) and a molecular weight of less than 500 may be absorbed, at least in part, via the dermal route. The partition coefficient of Sakuralube S-900 is log Pow >4.64 and the molecular weight is 920-1200 Da.; accordingly, it is not considered likely that this material will cross the skin barrier. Although there were some signs of dermal irritation noted these were resolved 2-7 days after dosing. There was no sign of toxicity or ill health in any rabbit during the observation period.

 

 

Inhalation route

There are no toxicokinetics or inhalation toxicity studies available with Sakuralube S-900.

 

Distribution

The findings from the 28-day repeat dose and reproductive/development screening tests did not provide evidence that Sakuralube S-900 was distributed systemically following oral administration. It was concluded that oral administration of Sakuralube S-900 to Sprague-Dawley CrI:CD®BR rats for 28-days at doses of 15, 150 and 1000 mg/kg/day (repeat dose test) or 100,300 and 1000 mg/kg/day (reproductive /development screening test) was well tolerated with no toxicologically significant adverse systemic effects. It was also concluded that there was no effect of treatment on reproductive performance, including mating performance, fertility and offspring survival and development up to Day 7 of age.

Metabolism

No data are available on metabolism in the existing toxicity studies.As no effects were seen in the repeat dose studies it cannot be stated with certainty that absorption of Sakuralube S-900 occurred.

 

Excretion

No data are available on excretion in the existing toxicity studies.

 

Conclusion

 

From the data available so far there is no evidence that the test substance is absorbed via the gastrointestinal tract following oral administration or via the skin following dermal administration.